Adding Medical Cannabis Leads to Improvements in Fibromyalgia Patients, Study Shows

Adding Medical Cannabis Leads to Improvements in Fibromyalgia Patients, Study Shows
Adding medical cannabis to standard pain relief therapy leads to clinical improvements in a significant proportion of patients with fibromyalgia, particularly among those with sleep problems and a lower body mass index (BMI), a new study has found. The study, “Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study,” was published in the journal Clinical and Experimental Rheumatology. Fibromyalgia is characterized by chronic widespread pain, fatigue, sleep dysfunction, and cognitive issues. Because the causes of fibromyalgia are largely unknown, finding effective treatments for the chronic condition is challenging. Additionally, patients often stop taking their medications because of limited efficacy and side effects. Hence, there is a significant need to identify more effective therapies. Medical cannabis treatment (MCT) is a recently introduced therapeutic option for patients who are dissatisfied with their current analgesic, or pain relief, treatment. MCT has been shown to be moderately effective in a range of chronic non-cancer pain conditions. However, few studies have investigated its effectiveness in patients with fibromyalgia. In the study, a group of Italian researchers set out to evaluate whether the addition of MCT to standard analgesic treatment might lead to clinical improvements in patients with fibromyalgia. Additionally, they analyzed the retention rate and whether there were any changes made to standard analgesic treatment over a period of six months. The study included 102 patients with fibromyalgia who, despite being on standard analgesic treatment, reported consistent mild or higher intensity pain (a score greater than four on the pain visual analogue scale) that lasted most of
Subscribe or to access all post and page content.